{"id":4701,"date":"2010-11-14T14:08:56","date_gmt":"2010-11-14T19:08:56","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?p=4701"},"modified":"2011-07-19T17:44:42","modified_gmt":"2011-07-19T21:44:42","slug":"new-lvad-shows-promise-as-bridge-to-transplant","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2010\/11\/14\/new-lvad-shows-promise-as-bridge-to-transplant\/","title":{"rendered":"New LVAD Shows Promise as Bridge-to-Transplant"},"content":{"rendered":"<p>ADVANCE (Evaluation of the HeartWare HVAD Left Ventricular Assist Device System for the Treatment of Advanced Heart Failure) evaluated the clinical efficacy of a novel small centrifugal flow pump\u00a0as a bridge-to-transplant. In the trial, 140 patients who received the device were compared to a contemporaneous control group of\u00a0499 similar patients who had received a commercially available LVAD as a bridge-to-transplant. <a href=\"http:\/\/www.newsroom.heart.org\/index.php?s=43&amp;item=1188\">Results of ADVANCE were presented on Sunday at the AHA meeting in Chicago.<\/a><\/p>\n<p>At 180 days, 92% of HVAD patients were alive, had received a transplant, or had recovered and no longer needed the device, compared to 90% of controls. This result met the predefined test for noninferiority (P&lt;0.001).\u00a0The 1-year survival rate was 91% in the HVAD group compared to 86% in the controls.<\/p>\n<p>Compared to baseline, HVAD-treated patients were able to walk farther (113 meters) and had significant improvements in several quality-of-life measures. The investigators reported that the HVAD had a favorable adverse event profile when used as a bridge-to-transplant and that &#8220;large quality of life and functional capacity improvements are similar to those obtained with cardiac transplantation.&#8221;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>ADVANCE (Evaluation of the HeartWare HVAD Left Ventricular Assist Device System for the Treatment of Advanced Heart Failure) evaluated the clinical efficacy of a novel small centrifugal flow pump\u00a0as a bridge-to-transplant. In the trial, 140 patients who received the device were compared to a contemporaneous control group of\u00a0499 similar patients who had received a commercially [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20,14],"tags":[555,287,554],"class_list":["post-4701","post","type-post","status-publish","format-standard","hentry","category-cardiac-surgery","category-heart-failure","tag-bridge-to-transplant","tag-heart-failure-2","tag-lvad"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/4701","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=4701"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/4701\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=4701"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=4701"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=4701"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}